TPG Places a Growth Bet On China's Drug Industry (China)
This article was originally published in PharmAsia News
Executive Summary
TPG, the private-equity firm formerly known as Texas Pacific Group, is investing in Shanghai ChemPartner, one of China's largest pharmaceutical-research outsourcing companies. TPG also will invest in ChemPartner's sister company, ChemExplorer, because the minority stake TPG is taking will actually be in ShangPharma, the recently formed holding company of both. ChemExplorer does most of its work for Eli Lilly & Co., while ChemPartner is an established outsourcer to many global drug firms. Multinational pharmaceutical firms are increasingly using Chinese scientists, and health care is drawing greater interest from venture capitalists and early-stage financiers, who previously avoided China's drug industry. (Click here for more - May Require Paid Subscription
You may also be interested in...
Shanghai ChemPartner CEO Michael Hui On Finding A Niche In China Amidst Increasing Foreign Competition: An Interview With PharmAsia News (Part 1 of 2)
Shanghai ChemPartner was set up in 2003 at Shanghai's Zhangjiang Hi-Tech Park, and today it is one of the leading R&D outsourcing providers in China. PharmAsia News recently visited company headquarters to meet Michael Hui, CEO of ChemPartner - as well as sister company ChemExplorer, and their holding company ShangPharma - to discuss the company's recent deal with private equity investment firm TPG, as well as handling increased competition from foreign firms moving into China.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.